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 Fig. S1. IR spectrum of [NiLN3]BF4. 
  
 Fig. S2. Photomicrographs of acridine orange/ethidium bromide-stained control A549 cells and 
A549 cells exposed for 24h (upper images) and 48 h (lower images) to complexes [NiL(NCS)]BF4 
and [NiLCl]BF4. Applied concentrations of complexes corresponded to 0.5 × IC50 values 
determined for 48 h. 
 
  
 Fig. S3. Dot plot diagrams obtained by flow-cytometric analysis of treated HeLa cells after dual 
staining with Annexin V-FITC and PI. Annexin V-FITC/PI staining was performed after 48 h of 
HeLa cells exposure to nickel complex ([NiL(NCS)]BF4 [NiL(N3)]BF4 [NiL(NCO)]BF4, 
[NiLCl]BF4) and CDDP with 40 μM concentration for nickel complexes and 5 μM concentration 
for cisplatin. Representative dot plots are given, presenting live cells at lower-left quadrant, FITC(-
)/PI(-); early apoptotic cells at lower-right quadrant, FITC(+)/PI(-); late apoptotic or necrotic cells 
at upper-right quadrant, FITC(+)/PI(+); and dead cells at upper-left quadrant, FITC(-)/PI(+). 
  
 Fig. S4. Effect of the Ni(II) complexes ([NiL(NCS)]BF4, [NiL(N3)]BF4, [NiL(NCO)]BF4 and 
[NiLCl]BF4) and cisplatin (CDDP) on cell cycle progression of HeLa cells following 48 h 
incubation with 40 μM concentration for nickel (II) complexes and 5 μM concentration for 
cisplatin. Histograms presented are representative of three independent experiments. 
  






























Fig. S5. Wavelength scan for hydrolysis of pNPP in the absence and presence of Ni(II) complexes 
and NaOH in 97.5 % DMSO. [pNPP] = 1 × 10–3 M; [Ni(II) complexes] = 5 × 10–5 M (in the NaOH 
control [NaOH] = 5 × 10–5 M). 
  
 Table S1. Hydrogen bonding geometry for [NiLN3]BF4. 
D – H ··· A d(D – H)/ Å d(H ··· A)/ Å d(D ··· A)/ Å <(DHA)/ º Symmetry 
transformation for 
acceptors 
C1–H1A∙∙∙F1 0.96 2.34 3.229(8) 154 x, 1/2-y, -1/2+z 
C1–H1B∙∙∙F3 0.96 2.48 3.358(9) 152 1/2-x ,-y, -1/2+z 
C2–H2A∙∙∙F3 0.96 2.44 3.367(8) 163 x, 1/2-y, -1/2+z 
C14–H14∙∙∙N6 0.93 2.61 3.358(8) 138 1/2+x, y, 1/2-z 
 
 
 
